Search Results

Enable Injections, Inc. announced the Company has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise and enFuse delivery technology to specific Roche development programs.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.

Enable Injections, Inc. and Serina Therapeutics announced a partnership to develop and commercialize SER-252 in combination with enFuse for the treatment of Parkinson’s disease.

Enable Injections, Inc., a company developing and manufacturing the enFuse® platform of wearable drug delivery systems, is pleased to announce the appointment of Vickie Capps to the company’s Board of Directors as the head of the audit committee.

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

Enable Injections, Inc. (“Enable”) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH).

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.